Inhibitor
An inhibitor is a substance that reduces the activity of a biological target, such as an enzyme, receptor, transporter, ion channel, signaling protein, or nucleic-acid-associated factor.
An inhibitor is a substance that reduces the activity of a biological target, such as an enzyme, receptor, transporter, ion channel, signaling protein, or nucleic-acid-associated factor. Inhibition may result from direct occupation of an active site, competition with a substrate or ligand, binding to an allosteric site, or disruption of a required protein–protein or protein–nucleic-acid interaction. In pharmacology, inhibitors are used to modulate disease-associated pathways, suppress pathogen functions, reverse drug resistance, and improve the selectivity or potency of therapeutic agents.
The recent literature represented here places inhibitors primarily within small-molecule drug discovery. The targets span human cancer biology, multidrug resistance, bacterial signaling, viral replication, neurological electrophysiology, and proteolytic or metabolic enzymes. Approaches include virtual screening, deep learning, fragment-based discovery, molecular generation, chemical conjugation, and analytical measurement of drug exposure. The corpus does not indicate a single biological pathway; instead, it extends the broad application of inhibitor design across cancer, glioma, breast cancer, infectious disease, and experimental neuroscience.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
55 papers study inhibitor directly. The themes below are drawn from those 55. 1 paradigm shift follows.
-
Targeted Cancer Therapy : Kinase inhibitors, PD-L1 agents, antibody-drug conjugates and PD-1 combinations are converging on precision cancer treatment. Mutation-selective EGFR activity, c-Met and FAK targeting, radiosensitization and immunogenic cell death recur as therapeutic endpoints. 17 papers · 30.9%
-
Synthetic Inhibitor Discovery : Synthesis, molecular docking and dynamics recur across antiviral, neuroprotective, antifibrotic and metabolic inhibitor programs. The work shares structure-guided optimization and potency testing rather than a single disease or target. 14 papers · 25.5%
-
Computational Inhibitor Discovery : Virtual screening, fragment discovery and deep learning are being paired with in vitro validation to identify small molecules against drug resistance, autophagy, neuroinflammation and bacterial signaling. Potency and resistance reversal remain recurring endpoints. 7 papers · 12.7%
-
Cancer Enzyme Vulnerabilities : Selective enzyme inhibitors are being linked to vulnerabilities in breast cancer stem cells, SMARCB1-deficient tumors and leukemia. Mitotic catastrophe, autophagy disruption, cellular stress and antiproliferative activity recur across these targeted programs. 5 papers · 9.1%
-
Brain Enzyme Inhibition : Rationally designed cholinesterase ligands recur, with multi-target activity, fluorescence detection and neuroprotective effects emphasized for Alzheimer disease. Carbonic anhydrase inhibition extends the focus to altered chloride dynamics and epileptiform activity. 4 papers · 7.3%
-
Others — Cross-Disease Therapeutic Targets : The cluster spans metabolic disease, HIV, antifungal therapy, stroke, cancer, ovarian syndromes and thrombosis, with computational, biochemical and clinical approaches represented. No shared biological question or direction unifies the targets. 8 papers · 14.5%
Inhibitors can be resistance-reversal partners rather than stand-alone disease suppressors
The ABCG2 inhibitor study in adriamycin-resistant breast-cancer cells, the Erm inhibitor study in MLSB-resistant clinical isolates, and the MerTK inhibitor study in ICB-resistant murine melanoma each challenge the assumption that inhibitor efficacy must come from directly suppressing the disease or pathogen. Instead, ABCG2 inhibition resensitized resistant cancer cells to adriamycin, allosteric Erm inhibition restored macrolide-class antibiotic activity, and MerTK inhibition restored responsiveness to anti-PD-1 treatment. This shifts the therapeutic role of an inhibitor toward disabling a resistance mechanism so that an otherwise ineffective treatment can work again 42734561Sep 42720463Sep 42379015Jun.
Recent Findings on Inhibitor
Medicinal Chemistry for Inhibitors: Crizotinib conjugation, rational scaffold design, and dynamic combinatorial chemistry are extending inhibitor discovery toward multitarget activity, high affinity, and controlled delivery 42705840Sep42462519Jul42454810Jul. Cholinesterase, urease, aldose reductase, carbohydrate-metabolism, TRPV1, FAAH, and FtsZ programs report strong in vitro inhibitory activity supported by molecular docking, molecular dynamics, and structure–activity relationships 42462519Jul42447748Jul42320119Jun42284877Jun42247873Jun42242015Jun. Several leads also showed antioxidant, neuroprotective, analgesic, antimalarial, antibacterial, or cellular activity, but most remain at in vitro, in silico, or early animal stages 42442298Jul42413399Jul42372459Jun42320119Jun42242015Jun. Structure-guided optimization improved selectivity and resistance profiles for AKR1C3, HIV-1 reverse transcriptase, CYP4Z1, and SARS-CoV-2 Mpro, while the Mpro study specifically requires cell-based antiviral and human-protease selectivity testing 42335733Jun42372457Jun42097058May42314596Jun. The field is moving toward multifunctional and reversible inhibitors with better blood-brain barrier permeability, pharmacokinetics, and cellular validation 42454810Jul42442298Jul42372459Jun42372457Jun.
Small-Molecule Inhibitor Discovery: Deep learning, fragment-based virtual screening, structure-based docking, and molecular generation are expanding small-molecule discovery across resistant cancer, neuroinflammation, fibrosis, autophagy, and infectious disease 42734561Sep42734496Sep42734502Sep42675543Sep42276357Jun42385395Jul. Experimental validation strengthened several computational predictions, including ABCG2 target engagement, BCL-2 inhibition, PDE9A-dependent anti-neuroinflammatory effects, ATG4B engagement, and p300 inhibition 42734561Sep42734502Sep42675543Sep42385395Jul42276357Jun. CpxA phosphatase and Erm inhibitors illustrate a complementary strategy that disarms bacteria or reverses antibiotic resistance through combination therapy rather than direct bactericidal activity 42725978Sep42720463Sep. Computational models also clarified allosteric crosstalk in HIV-1 reverse transcriptase and generated selective MMP-12 predictions, although the MMP-12 framework lacks experimental validation 42725963Sep42734518Sep. Ongoing work emphasizes interpretable models, dynamic interaction analysis, ligand-efficient fragments, direct target engagement, and assays that improve translational assessment 42734496Sep42734518Sep42442094Jul42298369Jun.
Cancer-Targeted Inhibitor Therapy: Targeted cancer inhibitors are increasingly paired with immune checkpoint blockade, radiotherapy, antibody-drug conjugates, or biomarker-defined treatment selection 42685702Sep42447749Jul42379015Jun42391326Jul42365672Jun. Enfortumab vedotin and PD-L1 inhibitor N02 enhanced antitumor effects through immunogenic cell death, immune activation, apoptosis, and radiosensitization in preclinical models 42685702Sep42447749Jul. FAK, TGF-βR1, VEGFR2, CDK4/6, KDM6A/B, FGFR, c-Met, and mutant EGFR inhibitors produced antiproliferative activity, cell-cycle arrest, apoptosis, or tumor growth inhibition, with several compounds showing favorable pharmacokinetics or tolerability 42462521Jul42379010Jun42341570Jun42269137Jun42134161May42134160May42085935May. Results also support biomarker-guided therapy, including MerTK PET for predicting ICB resistance and pediatric patient-derived xenografts for validating MTAP-deficient tumors and patient-specific hypotheses 42379015Jun42391326Jul. Development is therefore moving toward mechanism-linked combinations and molecular stratification, while the reported evidence remains predominantly preclinical 42685702Sep42379015Jun42269137Jun.
Antiviral Enzyme Inhibitors: Cap-dependent endonuclease, mRNA decapping scavenger, influenza polymerase, and SARS-CoV-2 3CL protease inhibitors are producing broad antiviral activity with increasing attention to resistance, oral exposure, and metabolic stability 42606356Aug42593929Aug42259148Jun42102470May. CEN inhibitors protected guinea pigs from lethal Lassa and Junin virus infections, while KJ001-12a retained influenza activity against the I38T resistance context and CG-0988 showed nanomolar activity against Omicron EG.5.1 with high oral availability 42606356Aug42259148Jun42102470May. Compound 17 extended DcpS inhibition into FHIT-low or deficient solid-tumor xenografts, demonstrating that enzyme-inhibitor development in this cluster also supports oncology applications 42593929Aug. A systems-genetic PMOS report separately identified SF3B1 inhibition as improving adiposity, hyperandrogenism, and insulin levels in mice, adding a metabolic disease direction to the cluster 42741937Sep.
Antifungal Sterol Inhibitors: Tetrazole-based CYP51 inhibition and natural-product-derived sterol-biosynthesis inhibition are addressing fungal growth with distinct chemical strategies 42322905Jun42269470Jun. Deuterated tetrazole CN-15D retained low minimum inhibitory concentrations, extended microsomal half-life approximately fourfold, and improved survival in a Galleria mellonella infection model 42322905Jun. Kakuol-derived trialkylamine 3n produced in vitro and cucumber antifungal activity, possibly through disruption of cell-membrane permeability, supporting further development as an antifungal agrochemical 42269470Jun.
Covalent BTK inhibitor management, PCSK9 inhibition, BCL-xL or MCL-1 inhibition, STING degradation, and colchicine-site inhibition link inhibitor therapy to clinical outcomes, inflammatory injury, senescent-cell vulnerability, and acute leukemia 42740716Sep42714476Sep42624085Aug42372458Jun42320118Jun. In CLL/SLL, early prolonged treatment interruption predicted inferior progression-free and overall survival, whereas proactive cBTKi switching shortened treatment gaps and improved outcomes 42740716Sep. Add-on alirocumab reduced intracranial stenosis and improved low-density lipoprotein cholesterol control after acute stroke, but the difference in recurrent stroke was not significant 42714476Sep. Preclinical studies identified STING PROTAC Zp17 for cisplatin-associated acute kidney injury and colchicine-site inhibitor III-3 for AML, while senescent cancer cells showed dependence on BCL-xL and MCL-1 42372458Jun42320118Jun42624085Aug. The work is moving toward timing-aware dosing, biomarker-defined vulnerabilities, targeted degradation, and mechanism-based combination therapy.
Written from 55 PubMed abstracts, each one cited by PMID above. Published: 2026-09-15. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.